Desai & Diwanji assists Anjan Drug in stake sale

0
1124
Desai & Diwanji pharmaceutical Anjan Drug
LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link

Desai & Diwanji advised Chennai-based active pharmaceutical ingredients (API) manufacturer Anjan Drug when it sold a controlling stake to Stepahead Business Services, a subsidiary of Singapore-based joint venture Gamot API.

Terms of the deal, which was signed on 3 August and closed on 9 October, were not disclosed.

Gamot API consists of a three-member consortium: PAG Capital, CX Partners and Samara Capital. AZB & Partners advised PAG Capital, while Platinum Partners advised CX Partners and Samara Capital.

You must be a subscribersubscribersubscribersubscriber to read this content, please subscribesubscribesubscribesubscribe today.

For group subscribers, please click here to access.
Interested in group subscription? Please contact us.

你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章,欢迎成为我们的订阅会员成为我们的订阅会员

已有集团订阅,可点击此处继续浏览。
如对集团订阅感兴趣,请联络我们

LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link